Celltex Therapeutics Corporation was mentioned in the Stem Cell Journals publication as one of the five largest stem cell therapy trials using MSCs to fight COVID in an article titled “Development of COVID‐19 Therapies from Birthing Tissues and Cord Blood”.
Learn MoreCelltex Therapeutics obtains approval from FDA to evaluate Celltex’s Mesenchymal Stem Cells as prevention against COVID-19 and Medistar Corporation’s biodefense HVAC filter to destroy nearly 100% of the virus
Learn MoreThe key to defeating and preventing COVID-19 may lie within our own cells, according to a San Antonio doctor who aims to prove that theory with several studies just recently approved by the U.S. Food and Drug Administration.
Learn MoreFormer U.S. Secretary of Energy and former Governor of Texas, Rick Perry, was on Fox News TV discussing Celltex’s COVID-19 ongoing clinical trials and the ingenuity that will deliver a victory over this virus.
Learn MoreCelltex has three ongoing COVID-19 clinical trials using Celltex’s TRUECELL™ Mesenchymal Stem Cells (MSCs), a Phase III and two Phase II.
Learn MoreDr. Derek W. Guillory, Founder and Medical Director of Root Causes Medicine in San Antonio and Principal Investigator for Celltex’s upcoming clinical trial was recently brought on as a guest of the Erick Erickson Show on WSB Radio.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. On March 21st, 2020, Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs) in the US.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. The journal Aging & Disease has recently reported on a study that has proven transplantation of mesenchymal stem cells has improved the outcome of 7 patients diagnosed with COVID-19 Pneumonia in Bejing, China.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells.
Learn More